Core Insights - CERo Therapeutics Holdings, Inc. has appointed Eric Francois to its Board of Directors, which is expected to enhance the company's strategic direction and operational capabilities [1][2]. Company Overview - CERo is an innovative cellular immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [3]. - The company’s proprietary approach integrates both innate and adaptive immunity to create a more effective therapeutic construct for tumor targeting [3]. Leadership and Expertise - Eric Francois brings over 25 years of experience in the life sciences sector, including significant roles in financial advisory and capital raising, having raised over $300 million during his tenure as CFO of SCYNEXIS [2]. - His expertise in mergers and acquisitions, along with business development, is anticipated to be a valuable asset for CERo at this stage of its growth [2]. Product Development - CERo has initiated clinical trials for its lead product candidate, CER-1236, targeting hematologic malignancies, showcasing its commitment to advancing innovative cancer therapies [3]. - The company’s unique Chimeric Engulfment Receptor T cells (CER-T) are designed to utilize phagocytic activity to destroy cancer cells, potentially offering advantages over existing CAR-T therapies [3].

Core Insights - CERo Therapeutics Holdings, Inc. announced a key clinical update regarding its CertainT-1 trial for patients with acute myeloid leukemia (AML), reporting cell expansion with no treatment-related adverse events observed to date [1][3] - The company has amended the CertainT-1 trial to include advanced myelodysplastic syndrome (MDS) and myelofibrosis (MF) as additional cohorts [2][3] - A conference call is scheduled for January 7, 2026, to discuss the trial's progress and the company's future strategy [5] Clinical Trial Update - The CertainT-1 trial has completed the dose-limiting toxicity observation period for the first cohort, with investigators noting a 61-day platelet transfusion-free interval after treatment with CER-1236, surpassing the 8-week benchmark commonly referenced in clinical studies [1][3] - The trial is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with AML, including those who are relapsed/refractory or newly diagnosed with TP53 mutated MDS/AML [3][4] - Primary outcome measures include the incidence of adverse events, dose-limited toxicities, and overall response rate, while secondary measures focus on pharmacokinetics [3] Strategic Expansion - The inclusion of MDS and MF in the trial is seen as a significant milestone, with the company emphasizing the importance of careful dose escalation and systematic safety data collection [4] - The CEO expressed gratitude to trial participants and shareholders, highlighting the company's commitment to advancing its clinical programs [4] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a novel cellular immunotherapy platform that integrates innate and adaptive immunity [7][8] - The company's lead product candidate, CER-1236, is currently in clinical trials for hematologic malignancies, aiming to offer advantages over existing CAR-T therapies [8]

Core Insights - CERo Therapeutics has received FDA approval for an amendment to its IND regarding Chemistry, Manufacturing, and Controls (CMC), allowing the company to initiate patient dosing in the first half of 2025 [1][2] - The company has also had an abstract accepted for presentation at the 2025 ASCO conference, scheduled for May 30 to June 5 in Chicago [2] - The Phase 1/1b clinical trial for CER-1236 will evaluate its safety and preliminary efficacy in patients with relapsed/refractory measurable residual disease positive acute myeloid leukemia [2][3] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [3] - The company aims to create Chimeric Engulfment Receptor T cells (CER-T) that can potentially target both hematological malignancies and solid tumors, offering a differentiated therapeutic application compared to existing CAR-T therapies [3]

Core Insights - CERo Therapeutics Holdings, Inc. is advancing its market position with the upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML) and has secured a manufacturing agreement with the University of California Davis for its product CER-1236, aiming to dose the first patient in the first half of 2025 [1][2] Company Overview - CERo is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [2] - The company’s Chimeric Engulfment Receptor T cells (CER-T) are designed to enhance the immune response against tumors by employing phagocytic mechanisms, potentially offering broader therapeutic applications than current CAR-T therapies [2] Clinical Development - The manufacturing of CER-1236 is a critical step before patient dosing, and the company is optimistic about progressing this process with UC Davis, a reputable institution in clinical trial manufacturing [2]

Core Insights - CERo Therapeutics Holdings, Inc. is presenting promising preclinical results for its lead compound CER-1236 in ovarian cancer at the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors [1] - The study demonstrated that CER-1236 effectively targets ovarian cancer cells without causing toxicity in animal models [2] - The CEO of CERo highlighted the efficacy and safety profile of CER-1236, indicating its potential utility across various cancer types, including ovarian and Non-Small Cell Lung Cancers [3] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [4] - The company aims to redirect patient-derived T cells to eliminate tumors through a novel cellular immunotherapy platform, referred to as Chimeric Engulfment Receptor T cells (CER-T) [4] - CERo plans to initiate clinical trials for CER-1236 in 2025, targeting both hematological malignancies and solid tumors [4]

Core Insights - CERo Therapeutics Holdings, Inc. is presenting promising preclinical results for its lead compound CER-1236 in ovarian cancer at the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors [1][2] - The study demonstrated that CER-1236 effectively targets ovarian cancer cells without causing toxicity in animal models, indicating a favorable safety profile [2][3] - The company plans to initiate clinical trials for CER-1236 in solid tumors in 2025, building on its previous findings in both ovarian and Non-Small Cell Lung Cancers (NSCLC) [3][4] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [4] - The company’s Chimeric Engulfment Receptor T cells (CER-T) are designed to enhance the immune response against tumors, potentially offering broader therapeutic applications than current CAR-T therapies [4]

New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting preclinical results of lead compound CER-1236 in ovarian cancer during the Spring Scientific from the Society for Immunothera ...